New hope for Hard-to-Treat cancers: GAIA-102 targets belly fluid in stomach and pancreatic cancer
NCT ID NCT05438459
First seen Nov 18, 2025 · Last updated May 13, 2026 · Updated 20 times
Summary
This study tests a new drug called GAIA-102, given alone or with another drug (pembrolizumab), for people with advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The first part checks safety and the best dose; the second part looks at whether it helps people live longer. About 130 participants will join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.